Cellectis US cap raise closes historic year for biopharma
Cellectis, the French gene-editing company, has launched a $100m US capital raising to help fund its research and development operations. The sector has had a record year for issuance in 2020, as the Covid-19 pandemic has concentrated minds on global healthcare innovation.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: